Allspring Global Investments Holdings LLC Reduces Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Allspring Global Investments Holdings LLC decreased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 99.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,112 shares of the company’s stock after selling 596,004 shares during the period. Allspring Global Investments Holdings LLC’s holdings in TransMedics Group were worth $207,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of TMDX. Quarry LP increased its position in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the period. National Bank of Canada FI raised its position in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the period. Hager Investment Management Services LLC purchased a new position in shares of TransMedics Group during the 4th quarter worth about $33,000. Finally, Sachetta LLC acquired a new position in shares of TransMedics Group in the 4th quarter valued at $40,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Trading Down 5.3 %

Shares of NASDAQ:TMDX opened at $73.00 on Wednesday. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a fifty day moving average price of $66.89 and a 200 day moving average price of $103.27. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $2.45 billion, a PE ratio of 77.66 and a beta of 2.12.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TMDX. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Robert W. Baird lowered their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Piper Sandler lowered their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.